The approval was based on data from 2 randomized, double-blind, placebo-controlled trials, ARCADIA 1 and ARCADIA 2.

The US Food and Drug Administration (FDA) has approved nemolizumab for moderate-to-severe atopic dermatitis inadequately ...

Dupilumab treatment improves signs and symptoms of atopic dermatitis (AD) in young children, according to a study p ...

Secondary endpoints at 16 and 24 weeks included Investigator Global Assessment (IGA) score of clear (0 ... with moderate-to-severe atopic dermatitis (eczema) that is not well controlled despite ...